Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BJ-001 +/- Pembrolizumab in Advanced Solid Tumors
NCT04294576Phase 1Active, not recruiting
- Sponsor
- BJ Bioscience Inc.
- Start
- Dec 2019
- Primary completion
- Apr 2024
- Modality
- Prophylactic Vaccines, Interleukins, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of interleukin-15 fusion protein BJ-001 in solid tumor (advanced stage) (2 arms), sponsored by BJ Bioscience Inc. Primary endpoints: Frequency of adverse events, Severity of Adverse Events and 2 more. Started Dec 2019; status: active, not recruiting.
02
Drugs
interleukin-15 fusion protein BJ-001
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04294576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04294576.